Objective: To investigate the in vitro antivirus effect of total flavonoid from Trollius ledebouri Reichb (TFTLR). Methods: Madin-Darby canine kidney (MDCK) and Human epithelial type 2 (HEp-2) cell lines were used to test the antivirus effect of TFTLR on nine virus subtypes: four H1N1, one H3N2, and four other subtypes prevalent in North China. Tamiflu, Ribavirin and Lianhua Qingwen were used as active comparators. Comprehensive molecular pathway analyses of TFTLR-H1N1 and TFTLR-H3N2 relationships were also conducted. 50 values against these viruses were 0.13, 0.07, 0.06, 0.14, and 0.07 mg/ml, respectively; and therapeutic index (TI) values were 8. 62, 16.0, 18.67, 8.0, and 16.0, respectively. TFTLR showed no effect on parainfluenza virus type 1, herpes simplex virus type 1, respiratory syncytial virus, and coxsackie group B virus type 4. Pathway analysis revealed possible functional therapeutic mechanisms for TFTLR against H1N1 and H3N2 infections. Conclusion: TFTLR may represent a potential therapeutic agent against influenza A subtypes H1N1 and H3N2 that are prevalent in North China, and should be investigated further.
Introduction
More than 90% percent of acute respiratory tract infections are induced by respirovirus. 1 Respirovirus invades the respiratory tract to cause local lesions, or takes the respiratory tract as an invasion path to cause ailments in other tissues or organs. 2 Types of virus that invade via the respiratory route include influenza virus, parainfluenza virus, respiratory syncytial virus, measles virus, mumps virus and adenovirus. 2 Respiratory virus antigens can mutate rapidly by antigenic drifting or antigenic switching, 2 and drug-resistant virus strains are continuously detected, demonstrated by reduced or total loss of treatment effect with existing drugs. For instance, Tamiflu is a well-recognized antiviral medication used to treat influenza A, 3 however, over time, Tamiflu-resistant subtypes of influenza A have been detected. 4, 5 Thus, there is ongoing demand for the development of novel drugs to treat respiratory virus infections.
In the present study, the antivirus effect of total flavonoid acquired from Trollius ledebouri Reichb (TFTLR) was tested on nine virus subtypes using in vitro cell lines. 6 Detected components include orientoside, vitexin, meletin, cirsimaritin, and orientin-2-O-b-galactoside, 6 however, these are yet to be quantitatively characterised. Despite the lack of characterisation, Chinese globeflower extract has been shown to be effective as a low-cost drug, native of North China, in the treatment of acute upper respiratory tract infection diseases, including tonsillitis, pharyngitis, acute tympanitis and acute lymphangitis. 7 Chinese globeflower appears to exert it's treatment effects on influenza virus infections by inhibiting viral replication, improving the immune function of the body, and improving blood circulation. 8 In addition, previous studies suggest that flavonoids are effective in treating influenza A (H1N1) 9 and related symptoms, including inflammation, cough and fever. [10] [11] [12] [13] Therefore, TFTLR acquired from Chinese globeflower may possess anti-respiratory virus effects that are worthy of further study.
The aims of the present study were to investigate: (A) the possible antiviral effect of TFTLR as a whole, on in vitro cell lines subjected to infection with nine viral subtypes; and (B) to conduct comprehensive multiple-level pathway analyses using Pathway Studio software, to study the functional associations between TFTLR and two influenza A subtypes, H1N1 and H3N2. 
Materials and methods

Experimental materials
Experimental methods
Toxicity of TFTLR on MDCK and HEp-2 cells. The TFTLR test solutions were prepared by diluting the stock solution 1:2 to 1:256 with DMEM. A total of 100 ml per well of TFTLR test solutions at different concentrations were added to monolayers of MDCK and HEp-2 cells that had been cultured in 24-well plates. Four wells were tested per TFTLR concentration. Normal control cells were cultured under the same conditions with 100 ml/well of DMEM without TFTLR added. Following the addition of TFTLR or control DMEM, the culture plates were incubated in a 5% CO 2 incubator at 37 C. Cell lesions ( rate of apoptotic/ damaged cells) were observed daily under an inverted phase contrast microscope (Olympus, Japan) to determine the minimum concentration that did not induce cell lesions (the maximum non-toxic concentration, TC 0 ). The median toxic concentration (TC 50 ) was calculated with ReedMuench assay. 14 In vitro antivirus effect of TFTLR. Cells were cultured to monolayers in 24-well plates, then the culture fluid was aspirated and the cell surface was washed 3 times in DMEM maintenance fluid. MDCK cells were inoculated with a volume of 100 ml/ well of each influenza virus strain at the following dilutions of original stocks: was then added into the MDCK and HEp-2 cell culture plates in volumes of 100 ml/well. Tamiflu (50 mg/ml), Lianhua Qingwen (35 mg/ml) and Ribavirin (10 mg/ml) were used as active comparators. Untreated control cells and virus inoculated positive control cells (without antiviral drug) were cultured simultaneously. All cells were cultured in a 5% CO 2 incubator at 37 C. Cell lesions were observed daily using an inverted phase contrast microscope. When the level of cell lesions exceeded 75% in the virus positive control, test results for all cells were recorded.
Cell lesions were divided into six levels: (1) Normal growing cells with no observable lesion; (2) The rate of cells with lesions <10% of the entire cell monolayer; (3) The rate of cells with lesions <25% of the entire cell monolayer; (4) The rate of cells with lesions <50% of the entire cell monolayer; 5) The rate of cells with lesions <75% of the entire cell monolayer; and (6) The rate of cells with lesions > 75% of the entire cell monolayer. Higher rates of cell lesions equated to less effective drug treatment.
The drug concentration that inhibited the number of cytopathies by 50% (IC 50 ) was calculated using the Reed-Muench method and the therapeutic index (TI) was calculated as follows: TI ¼ TC 50 /IC 50 . Results were not statistically analysed.
Pathway analyses. Molecular level pathway analyses were conducted to study the potential association between total flavonoid and influenza virus subtypes H1N1/H3N2, using Pathway Studio, version 11.4 (www.path waystudio.com). Pathway Studio has been widely used to study modelled relationships between proteins, genes, complexes, cells, tissues and diseases (http://pathwaystudio.gou sinfo.com/Mendeley.html). 15 Updated weekly, the Pathway Studio ResNet database is the largest database among known competitors in the field. 16 
Results
Cell toxicity of TFTLR on MDCK and HEp-2 cells
The TC 0 and TC 50 of TFTLR and the three positive control drugs (Tamiflu, Ribavirin and Lianhua Qingwen) on MDCK and HEp-2 cells are presented in Table 1 Lianhua Qingwen showed minor inhibitory effect on HEp-2 cell lesion induced by PIV-1 and HSV-1 (Table 4) .
Pathway analyses
Since TFTLR demonstrated strong antivirus effects for both H1N1 and H3N2 subtypes, comprehensive pathway analyses were performed to study the possible association between total flavonoid and both H1N1 and H3N2 at the molecular level.
Pathway analyses showed that flavonoid may be linked to both H1N1 and H3N2 through multiple pathways, as shown in Figure 1 . Different flavonoids have been observed to inhibit influenza A virus replication, 17 possibly through the flavonoids inhibiting viral reproduction and stimulating autophagy, 18 which in turn may mediate antiviral immunity. 19 Moreover, flavonoids may attenuate influenza A related symptoms, such as fever, cough, inflammation and immune response, possibly through the inhibition of important regulatory enzymes involved in arachidonic acid metabolism. 20 Pathway analysis also showed that the anti-influenza A virus effect of flavonoid may involve mechanisms at the genetic level. As shown in Figure 1 , flavonoids induce the activation of nuclear factor, erythroid 2 like 2 (NFE2L2), 21 while NFE2L2 activation can reduce influenza A H3N2. 22 In addition, flavonoids can significantly decrease the gene expression of interleukin (IL)-6 and tumour necrosis factor (TNF)-a, 23 while IL-6 and TNF-a are biomarkers of influenza A H1N1 infections. 24 This may also partly explain why flavonoids can inhibit influenza A-related symptoms, including fever, cough and inflammation, all of which are related to the activity of IL-6 and TNF-a. 11 Supporting references for each relationship in Figure 1 are available for download via the following weblink: (http://gousinfo. com/database/Data_Genetic/Network_sup 
porting_info_Flavonoids.xlsx).
This weblink includes the relationship type, titles, and related sentences where a relationship has been identified. This information can be used to identify the detailed descriptions regarding how flavonoids may contribute to the treatment of influenza A virus infection.
Discussion
Trollius ledebouri Reichb, of the Ranunculaceae family, is one type of Chinese globeflower used for the treatment of acute upper respiratory tract infections, tonsillitis, pharyngitis, acute tympanitis, and acute lymphangitis. 7 Total flavonoid is the natural product and the main effect fraction of T. ledebouri Reichb, and its components include orientoside, vitexin, meletin, cirsimaritin, and orientin-2-Ob-galactoside. 6 Previous studies have shown that TFTL and TFTLR have significant antibacterial, anti-inflammatory, antipyretic and antiviral effects. 12, 13 Due to the complexity of quantitatively measuring the sub-components of TFTLR, the current study focused on testing the antiviral effect of TFTLR as a whole.
To better evaluate the antiviral effect of TFTLR, the present study tested the in vitro pathways that connect flavonoid and the influenza A subtypes H1N1 and H3N2 (Figure 1 ). For example, a flavonoids-NFE2L2-H3N2 pathway was revealed, in which flavonoids induce the activity of NFE2L2, 25 and NFE2L2 activation can reduce the activity of H3N2. 22 A flavonoids-IL-6-H1N1 pathway was also revealed, in which flavonoids inhibit the production of IL-6 (pro-inflammatory cytokines), 26 while IL-6 plays a role in the development of H1N1 infection. 27 These may partially explain the anti-H1N1 effect of flavonoids. 10 Plant flavonoids have also been reported to attenuate the immune response and interfere with viral reproduction, 17 which adds background evidence to the findings that flavonoids can inhibit influenza A related symptoms including fever, cough and inflammation. 11, 28 The results of the present study are limited by several factors. First, the results regarding the therapeutic effects of TFTLR were not statistically analysed. Although TFTLR appeared to demonstrate effectiveness on H1N1 subtypes and the H3N2 subtype in MDCK cells, the results of the study need to be investigated further to elucidate the antiviral properties of flavonoids using drugs tests, or via complementary treatments using TFTLR, in humans and human cell types in vitro. Further, the present study employed cell line experimental data and literature-based pathway analysis to study the anti-influenza virus effect of TFTLR. Another effective approach for further investigation would be to use, e.g., gene expression data, to analyse the TFTLR treatment effect on anti-influenza virus. Finally, the present study tested the treatment effect of TFTLR as a whole extract, however, TFTLR comprises multiple chemical components. Thus, the antivirus function of the subcomponents of TFTLR should be studied to determine which are the active components in TFTLR, in order to facilitate the understanding of its treatment mechanisms.
In conclusion, both in vitro cell-line experiments and pathway analysis supported the effectiveness of TFTLR in treating influenza A subtypes H1N1 and H3N2 infections that are prevalent in North China. With relatively low cost, the results of the present study suggest that TFTLR from T. ledebouri Reichb may possess therapeutic potential for the treatment of influenza A versus infections. The results of the present study also suggest that TFTLR may not be an effective drug candidate for treating infections caused by PIV-1, HSV-1, RSV and CoxB4 viruses. To the best of the present authors' knowledge, this is the first study to test the antivirus effect of TFTLR extracted from Chinese globeflower, which is native to Northeast China. Considering the component complexity of TFTLR, the authors suggest that further investigations are required to evaluate the antivirus effect of TFTLR on respiratory viruses that are prevalent in North China.
